Adial Pharmaceuticals, Inc. — Q1 2023 Form 10-Q
Reporting period: Three months ended March 31, 2023. Adial is a clinical-stage biopharmaceutical company developing AD04 for alcohol use disorder (AUD); it has no approved products and reported no product revenue.
Financial performance and position
| Metric | Q1 2023 | Q1 2022 / comparison |
|---|---|---|
| Revenue | No product revenue | No product revenue |
| Research and development expense | $676,435 | $596,341; up 13% |
| General and administrative expense | $2,244,293 | $2,462,613; down 9% |
| Total operating expenses / operating loss | $2,920,728 | $3,058,954 |
| Net loss | $2,905,836 | $2,907,839 |
| Basic and diluted loss per share | $0.11 | $0.13 |
| Cash used in operating activities | $2,298,813 | $2,496,753 |
| Cash from financing activities | $609,613 | $9,123,741 |
- Cash and cash equivalents were $2.31 million at March 31, down from $4.00 million at December 31, 2022. Total assets were $3.90 million; total liabilities were $2.46 million; stockholders’ equity was $1.44 million.
- Current liabilities were $1.80 million. The filing reports lease liabilities of $193,796, contingent liabilities of $506,000, and no conventional borrowings identified in the presented balance sheet.
- There was no meaningful revenue margin to assess. Operating expenses were primarily R&D and G&A; the company remained loss-making.
- Cash equivalents exceeded FDIC insurance limits by approximately $246,000; the company reported about $1.8 million in non-FDIC-insured cash equivalent accounts.
Changes and notable items
- Net loss was nearly unchanged year over year. Reported R&D expense rose $80,000, partly because a favorable prior-year accrual adjustment did not recur; excluding that effect, management said R&D expense decreased about $243,000 as trial activity wound down and Purnovate spending was reduced.
- G&A fell $219,000, mainly from lower equity compensation, partly offset by higher cash compensation, patent costs, and legal expenses.
- In February, Adial issued 1,829,269 shares for gross proceeds of $750,000 and net proceeds of $609,613, and issued placement-agent warrants for 182,927 shares. Common shares outstanding were 28,516,564 at March 31.
- After quarter-end, on May 8, Adovate exercised its option to acquire Purnovate’s assets. Adial received a $450,000 fee and expects reimbursement of certain prior Purnovate expenses, estimated by management at approximately $900,000. The proposed final terms include 19.99% equity in Adovate, royalties, and contingent development, approval, and commercial milestone payments; these are subject to the acquisition arrangements and conditions described in the filing.
Outlook, risks, and contingencies
- Going concern and financing: Adial states that cash on hand is not sufficient to fund operations for the 12 months following filing and that substantial doubt exists about its ability to continue as a going concern. Management estimated that reduced Purnovate-related cash burn, the $450,000 option fee, and expected reimbursements could support operations into the first quarter of 2024, but additional funding is required. The company gave no assurance that financing will be available on acceptable terms or at all.
- Management estimates that a second Phase 3 trial of AD04 would require $8–12 million. Without additional capital, the company may delay, scale back, or discontinue programs, including further AD04 development.
- Management reported ONWARD Phase 3 data showing a statistically significant reduction in heavy-drinking days in a prespecified subgroup. The company was pursuing FDA and European regulatory discussions and potential partners; approval and commercialization remain uncertain. The filing says commercialization, if achieved, is not expected before 2025 or later.
- Adial disclosed material weaknesses in internal control over financial reporting, including deficiencies in risk assessment, documentation, review and approval processes, GAAP expertise, IT controls, and segregation of duties. Management concluded disclosure controls were not effective.
- Other risks include clinical and regulatory uncertainty, competition, financing and dilution risk, and possible increases in operating costs. The company reported no pending legal actions as of March 31 and no material off-balance-sheet arrangements.
Important facts for investors to verify
- Current cash runway and whether the expected Purnovate expense reimbursement was received, as well as completion and terms of the final asset acquisition.
- Available financing, expected funding needs, and the timing, cost, and regulatory path for any further AD04 trial.
- Regulatory feedback on the ONWARD results and the evidence supporting the targeted patient subgroup.
- Progress remediating disclosed internal-control weaknesses and any subsequent changes in control effectiveness.
- Potential dilution from outstanding warrants, options, and any future equity financing; confirm the status of the authorized reverse-stock-split proposal.